FDA — authorised 13 December 2024
- Application: NDA218808
- Marketing authorisation holder: NEUROCRINE
- Local brand name: CRENESSITY
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Crenessity in United States
FDA authorised Crenessity on 13 December 2024
Marketing authorisations
FDA — authorised 13 December 2024
- Application: NDA218820
- Marketing authorisation holder: NEUROCRINE
- Local brand name: CRENESSITY
- Indication: SOLUTION — ORAL
- Status: approved
FDA
- Marketing authorisation holder: NEUROCRINE
- Status: approved
Crenessity in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Nephrology approved in United States
Frequently asked questions
Is Crenessity approved in United States?
Yes. FDA authorised it on 13 December 2024; FDA authorised it on 13 December 2024; FDA has authorised it.
Who is the marketing authorisation holder for Crenessity in United States?
NEUROCRINE holds the US marketing authorisation.